Edition:
India

BIOLASE Inc (BIOL.OQ)

BIOL.OQ on NASDAQ Stock Exchange Capital Market

1.65USD
22 Jul 2019
Change (% chg)

$0.07 (+4.43%)
Prev Close
$1.58
Open
$1.56
Day's High
$1.68
Day's Low
$1.56
Volume
4,669
Avg. Vol
4,056
52-wk High
$2.86
52-wk Low
$0.91

Latest Key Developments (Source: Significant Developments)

Archon Capital Management Reports A Passive Stake Of 7.66% In Biolase As Of June 25, 2019
Friday, 5 Jul 2019 

July 5 (Reuters) - BIOLASE Inc ::ARCHON CAPITAL MANAGEMENT REPORTS A PASSIVE STAKE OF 7.66% IN BIOLASE AS OF JUNE 25, 2019.  Full Article

Biolase Reports 2018 Fourth Quarter And Full Year Results
Wednesday, 6 Mar 2019 

March 5 (Reuters) - BIOLASE Inc ::BIOLASE REPORTS 2018 FOURTH QUARTER AND FULL YEAR RESULTS.Q4 NON-GAAP LOSS PER SHARE $0.13.Q4 LOSS PER SHARE $0.33.Q4 REVENUE ROSE 3 PERCENT TO $13 MILLION.CASH, CASH EQUIVALENTS, AND RESTRICTED CASH TOTALED $8.3 MILLION AS OF DECEMBER 31, 2018.  Full Article

Biolase Inc - On January 25 Company Entered Into A Settlement Agreement With Cao Group, Inc -SEC Filing
Thursday, 31 Jan 2019 

Jan 31 (Reuters) - BIOLASE Inc ::BIOLASE INC - ON JANUARY 25 COMPANY ENTERED INTO A SETTLEMENT AGREEMENT WITH CAO GROUP, INC -SEC FILING.BIOLASE INC - CAO HAS AGREED TO DISMISS WITH PREJUDICE PREVIOUSLY-DISCLOSED LAWSUITS FILED BY CAO AGAINST COMPANY IN APRIL 2012 AND JANUARY 2018.  Full Article

Biolase Inc - On Sep 27, Co Entered Into Business Financing Modification Agreement With Western Alliance Bank
Thursday, 4 Oct 2018 

Oct 3 (Reuters) - BIOLASE Inc ::BIOLASE INC - ON SEPTEMBER 27, CO ENTERED INTO BUSINESS FINANCING MODIFICATION AGREEMENT WITH WESTERN ALLIANCE BANK - SEC FILING.BIOLASE INC - WESTERN ALLIANCE REDUCED CREDIT LIMIT UNDER BUSINESS FINANCING AGREEMENT TO $2.5 MILLION.  Full Article

Biolase Q2 Non-Gaap Loss Per Share $0.20
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - BIOLASE Inc ::BIOLASE REPORTS 2018 SECOND QUARTER RESULTS.Q2 NON-GAAP LOSS PER SHARE $0.20.Q2 LOSS PER SHARE $0.24.Q2 REVENUE ROSE 1 PERCENT TO $12.2 MILLION.AS OF JUNE 30, 2018, HAD ABOUT $14.4 MILLION IN WORKING CAPITAL.CASH AND RESTRICTED CASH TOTALED $3.1 MILLION ON JUNE 30, 2018, AS COMPARED TO $11.9 MILLION ON DEC 31, 2017.  Full Article

BIOLASE Names Todd A. Norbe President, Chief Executive Officer
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - BIOLASE Inc ::BIOLASE NAMES TODD A. NORBE PRESIDENT, CHIEF EXECUTIVE OFFICER.BIOLASE INC - JOHN R. BEAVER PROMOTED TO EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER.  Full Article

Biolase Announces 1-For-5 Reverse Stock Split Common Stock Will Begin Trading On Split-Adjusted Basis On May 11
Thursday, 10 May 2018 

May 10 (Reuters) - BIOLASE Inc ::BIOLASE ANNOUNCES 1-FOR-5 REVERSE STOCK SPLIT COMMON STOCK WILL BEGIN TRADING ON SPLIT-ADJUSTED BASIS ON MAY 11.BIOLASE INC - 1-FOR-5 REVERSE STOCK SPLIT WILL BECOME EFFECTIVE AT 11:59 P.M. ET ON THURSDAY, MAY 10, 2018.  Full Article

Biolase Has Asked Jonathan Lord Chairman Of Board Of Biolase, To Lead Co's Exploration Of Strategic Alternatives
Wednesday, 11 Apr 2018 

April 11 (Reuters) - BIOLASE Inc ::HAS ASKED JONATHAN T. LORD CHAIRMAN OF BOARD OF BIOLASE, TO LEAD CO'S EXPLORATION OF STRATEGIC ALTERNATIVES.BOARD HAS ALSO APPOINTED CHIEF FINANCIAL OFFICER JOHN BEAVER AS INTERIM CHIEF EXECUTIVE OFFICER.BEAVER REPLACES HAROLD FLYNN, JR., WHO HAS RESIGNED FROM HIS POSITIONS AS PRESIDENT AND CHIEF EXECUTIVE OFFICER.STRATEGIC ALTERNATIVES MAY INCLUDE A MERGER OR OTHER BUSINESS COMBINATION WITH ANOTHER PARTY.  Full Article

Biolase Files For Possible Resale Of Up To 21.9 Mln Shares Of Common Stock By Selling Stockholders
Wednesday, 17 Jan 2018 

Jan 16 (Reuters) - Biolase Inc ::BIOLASE INC FILES FOR POSSIBLE RESALE OF UP TO 21.9 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING.  Full Article

Biolase reports Q3 non-GAAP loss per share $0.05
Thursday, 2 Nov 2017 

Nov 1 (Reuters) - Biolase Inc :Biolase reports 2017 third quarter and nine-month results.Q3 non-GAAP loss per share $0.05.Q3 loss per share $0.06.Q3 revenue rose 18 percent to $10.8 million.  Full Article